Experimental synthetic pentadecapeptide
BPC-157 is an experimental 15-amino-acid peptide promoted for tissue repair and gut health. Most supporting evidence comes from animals or laboratory models. Published human reports are small and uncontrolled, while a new Phase 2 hamstring-strain trial is recruiting without results.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Several small human reports, one historical controlled abstract, and a recruiting Phase 2 trial sit beneath a much larger preclinical literature.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human findings are too small, uncontrolled, incomplete, or unpublished to establish injury healing, gastrointestinal benefit, or population safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: A registered protocol shows that the route is being studied; it does not establish effectiveness, safety, or an amount to use. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
The short version
BPC-157 is an experimental 15-amino-acid peptide promoted for tissue repair and gut health. Most supporting evidence comes from animals or laboratory models. Published human reports are small and uncontrolled, while a new Phase 2 hamstring-strain trial is recruiting without results.
Includes three small published human reports, the historical ulcerative-colitis meeting abstract summarized by FDA, two trial registrations without results, FDA's July 2026 evidence review, the July 23 advisory vote, and the 2026 WADA list.
What the evidence says
A 53-person randomized ulcerative-colitis study is known only through a meeting abstract summarized by FDA and was judged insufficient to support effectiveness. The published full papers are smaller uncontrolled reports.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether BPC-157 improves objective healing, function, return-to-activity time, or meaningful gastrointestinal outcomes in controlled human trials, and whether repeated exposure is safe.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
FDA reported mean Disease Activity Index changes of −3.2 with BPC-157 and −1.6 with placebo. The estimated between-group difference was 1.6 points with a 95% confidence interval from −4.84 to 1.62.
No results are posted. The registration describes the first sizable controlled human trial designed to test whether BPC-157 adds benefit to a standardized rehabilitation program.
The two participants had no reported adverse effects or meaningful short-term laboratory changes during the pilot.
Ten of 12 participants reported complete symptom resolution and two reported 80% improvement after the procedure.
Sixteen people were reached for follow-up and 14 reported some relief. The report did not use a control group, blinded assessment, standardized pain scale, or follow-up imaging.
Administration and handling
Published and registered human research has used materially different routes: rectal enema, intra-articular injection, intravesical administration, intravenous infusion, and a recruiting subcutaneous trial. These studies do not establish an approved route, dose, schedule, injection site, or interchangeable formulation. The Phase 2 hamstring registration does not publicly disclose its BPC-157 dose.
No FDA-approved BPC-157 product, regulator-approved consumer reconstitution procedure, or official storage instructions were located. FDA also identified characterization gaps involving free base versus acetate, impurities, aggregates, bioburden, and bacterial endotoxins. Vendor instructions should not be presented as official stability guidance.
Primary-source ledger
2026-07-23
2026-07-23
2026-02-27 · NCT07437547
2026-01-01
2025-09-01 · PMID 40131143
2025-08-06 · PMID 40756949 · DOI 10.1177/15563316251355551
2024-10-01 · PMID 39325560
2021-07-01 · PMID 34324435
2015-12-22 · NCT02637284
2003-11-01 · PMID 14554208 · DOI 10.1016/S0736-0266(03)00110-4